Clinical Goals and Barriers to Effective Psoriasis Care.

Autor: Strober BE; University of Connecticut Health Center, Farmington, CT, USA. brucestrober30@me.com.; Probity Medical Research, Waterloo, ON, Canada. brucestrober30@me.com., van der Walt JM; International Psoriasis Council, St. Louis, MO, USA., Armstrong AW; University of Southern California, Los Angeles, CA, USA., Bourcier M; Faculty of Medicine, Sherbrooke University, Sherbrooke, QC, Canada., Carvalho AVE; Moinhos de Vento Hospital Complex, Porto Alegre, Brazil., Chouela E; University of Buenos Aires, Buenos Aires, Argentina., Cohen AD; Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.; Department of Quality Measurements and Research, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel., de la Cruz C; Clínica Dermacross, Santiago, Chile., Ellis CN; Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI, USA., Finlay AY; Department of Dermatology and Academic Wound Healing, Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK., Gottlieb AB; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Gudjonsson JE; Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI, USA., Iversen L; Department of Dermatology, Aarhus University Hospital, 8000, Aarhus C, Denmark., Kleyn CE; The Dermatology Centre, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Barnes Building, Manchester, UK., Leonardi CL; St Louis University Medical School, St. Louis, MO, USA., Lynde CW; University of Toronto, Toronto, ON, Canada., Ryan C; Blackrock Clinic Dublin and University College Dublin, Dublin, Ireland., Theng CT; Department of Dermatology, National Skin Centre, Singapore, Republic of Singapore., Valenzuela F; Department of Dermatology, Universidad de Chile, Santiago, Chile., Vender R; Dermatrials Research Inc & Venderm Innovations in Psoriasis, Hamilton, ON, Canada., Wu JJ; Dermatology Research and Education Foundation, Irvine, CA, USA., Young HS; The Dermatology Centre, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Barnes Building, Manchester, UK., Kimball AB; Harvard Medical Faculty Physicians, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Jazyk: angličtina
Zdroj: Dermatology and therapy [Dermatol Ther (Heidelb)] 2019 Mar; Vol. 9 (1), pp. 5-18. Date of Electronic Publication: 2018 Dec 21.
DOI: 10.1007/s13555-018-0279-5
Abstrakt: Engaging global key opinion leaders, the International Psoriasis Council (IPC) held a day-long roundtable discussion with the primary purpose to discuss the treatment goals of psoriasis patients and worldwide barriers to optimal care. Setting clear expectations might ultimately encourage undertreated psoriasis patients to seek care in an era in which great gains in therapeutic efficacy have been achieved. Here, we discuss the option for early treatment of all categories of psoriasis to alleviate disease impact while emphasizing the need for more focused attention for psoriasis patients with mild and moderate forms of this autoimmune disease. In addition, we encourage policy changes to keep pace with the innovative therapies and clinical science and highlight the demand for greater understanding of treatment barriers in resource-poor countries.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje